Quick Answer
iBio, Inc. reported Revenue (ASC 606) of $400.0 thousand for fiscal year 2025.
iBio, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $400.0K | +77.8% |
| 2024 | $225.0K | — |
| 2023 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $0.00 | -100.0% | -100.0% |
| September 30, 2025 | $100.0K | — | — |
| March 31, 2025 | $0.00 | — | -100.0% |
| December 31, 2024 | $200.0K | — | — |
| September 30, 2024 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $50.0K | — | — |
- iBio, Inc. showed an increase of +77.8% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from iBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 5, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: